Hybio Pharmaceutical and iCarbonX Intelligent Peptide Deepen Strategic Cooperation, Signing Two Agreements on Innovative Drug CRDMO Services and Strategic Investment
July 1, 2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and Shenzhen iCarbonX Intelligent Peptide Pharmaceutical Technology Co., Ltd. (referred to as "iCarbonX Intelligent Peptide") held a signing ceremony in Shenzhen. Zeng Shaogui and Wang Jun, Chairmen of both parties, attended the signing ceremony and delivered speeches. Management personnel from both sides, including Yu Pinxiang, Tang Yangming, Yang Di, Chen Jiantao, Li Yingrui, Zhan Wenhu, Xiao Bin, and Wu Chun, were present to witness the event.
At this signing ceremony, the two parties formally signed both the Strategic Cooperation Agreement on Innovative Drug CRDMO Services and the Strategic Investment Agreement, marking a further deepening and upgrading of their strategic cooperative relationship.
Strategic Cooperation on Innovative Drug CRDMO Services
According to the Strategic Cooperation Agreement on Innovative Drug CRDMO Services, Hybio Pharmaceutical will give full play to its technical platform and industrialization advantages in the field of peptide drug CRDMO to fully support the development of multiple innovative drug projects under iCarbonX Intelligent Peptide, covering pipelines such as PDC (Peptide-Drug Conjugate) and AI-developed antimicrobial peptides. The cooperation will span the entire process from preclinical research to commercialization, involving key links such as API Process Optimization, formulation development, quality research, registration and declaration, and large-scale production.
Synergistic Effects of Strategic Equity Investment
On this basis, Hybio Pharmaceutical will make an equity investment in iCarbonX Intelligent Peptide through the Strategic Investment Agreement, further binding the cooperative relationship and deeply participating in the future development of iCarbonX Intelligent Peptide.
As a leading enterprise deeply rooted in the peptide industry, Hybio Pharmaceutical boasts internationally advanced comprehensive capabilities in peptide drugs, small nucleic acid drugs, and global commercialization. iCarbonX Intelligent Peptide, relying on its leading capabilities in peptide drug design and discovery, is advancing the research and development of multiple drugs with advanced mechanisms, and its "peptide chip + artificial intelligence" screening technology leads the world.
iCarbonX Intelligent Peptide has strong R&D strength and is efficiently advancing multiple cutting-edge projects. The iCPDC-001 project is a peptide-drug conjugate targeting a key protein in the tumor microenvironment, focusing on precise drug delivery in tumor stroma. It has great potential in the treatment of solid tumors such as triple-negative breast cancer and pancreatic cancer, having completed PCC (Preclinical Candidate Compound) screening and in vitro and in vivo validation, with plans to initiate IND-enabling studies in 2025. Another project is a structurally novel antimicrobial peptide developed based on the peptide chip platform combined with AI, featuring excellent broad-spectrum antibacterial activity (especially against drug-resistant bacteria, with MIC values of 2-16µg/mL) and showing Best-In-Class potential. It has completed Pre-IND submissions in China and the United States, with favorable safety and stability, and complete formulation processes and data packages.
Outlook for Deepened Cooperation
Since the signing of the Strategic Cooperation Framework Agreement in 2024, the two parties signed the Joint Development Agreement on GLP-1R/GIPR/GCGR Triple Agonists in May 2025, specifying that Hybio Pharmaceutical will lead preclinical and pharmaceutical development.
Given the excellent synergistic effects and remarkable achievements demonstrated in previous cooperation, to maximize the potential of complementary resources and realize the strategic value of advantage ，the two parties have decided to deepen their strategic alliance. This strategic investment aims to consolidate and upgrade this strong partnership, jointly leading the forefront of peptide drug innovation.
In the future, Hybio Pharmaceutical and iCarbonX will continue to uphold the cooperative philosophy of "complementary advantages, resource sharing, and collaborative innovation," jointly promoting the high-quality development of China's peptide innovative drugs to benefit patients worldwide.
About Hybio Pharmaceutical
Hybio Pharmaceutical is a national high-tech enterprise specializing in the integrated R&D, production, and sales of peptide and oligonucleotide drugs. It possesses internationally advanced comprehensive capabilities in the industrialization and marketing of peptide and oligonucleotide drugs, and is committed to providing more effective treatment options for patients through technological innovation and high-quality products, driving the development of the pharmaceutical industry.
About iCarbonX Intelligent Peptide
As a pharmaceutical platform under iCarbonX, iCarbonX Intelligent Peptide is based on independently developed silicon-based peptide chip technology and uses high-throughput data to train and generate AI Drug Discovery and optimization models. It is dedicated to empowering biopharmaceutical and technology companies, accelerating the development of macromolecular new drugs, improving drug bioactivity, stability, and targeting, meeting clinical transformation needs, bringing new vitality and possibilities to the field of drug R&D, and facilitating more efficient drug development in the industry.